A study to assess safety and tolerability as well as absorption and excretion of TC-5214 in medically stable elderly subjects

Study identifier:D4130C00013

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability and pharmacokinetics of TC-5214 given as multiple ascending oral doses in medically stable elderly subjects

Medical condition

Elderly subjects 65 years and older, healthy or with a stable disease and treatment.

Phase

Phase 1

Healthy volunteers

Yes

Study drug

TC-5214, Placebo

Sex

All

Actual Enrollment

32

Study type

Interventional

Age

65 Years +

Date

Study Start Date: 01 Jan 2011
Primary Completion Date: 01 May 2011
Study Completion Date: 01 May 2011

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria